The upcoming DyNAMic trial (unrelated to DYNAMIC colorectal study) of adaptive vs. continuous targeted therapy in BRAF mutant melanoma will use the same assay to guide timing of adaptive therapy treatment intervals (ISRCTN14643179).110. This evidence concerns the gene BRAF and melanoma.